Won-Yong Lee

MD. Ph.D.
Co-Founder
Chief Executive Officer


- MD. from Seoul National University School of Medicine

- Ph.D. from Sungkyunkwan University

- Otolaryngologist - Head and Neck Surgery training at Samsung Medical Center 

- Fellow at Seoul National University Hospital 

- Assistant professor at Busan National University Hospital 

- 15+ years of clinical experience in facial plastic surgery and procedures for anti-aging and reconstruction


The development of new drugs that provide a 'second chance' to patients without therapeutic options. This is the reason and goal of founding SHIFTBIO.  

Won-Yong Lee

MD. Ph.D.
Co-Founder
Chief Executive Officer


- MD. from Seoul National University School of Medicine

- Ph.D. from Sungkyunkwan University

- Otolaryngologist - Head and Neck Surgery training at Samsung Medical Center 

- Fellow at Seoul National University Hospital 

- Assistant professor at Busan National University Hospital 

- 15+ years of clinical experience in facial plastic surgery and procedures for anti-aging and reconstruction


The development of new drugs that provide a 'second chance' to patients without therapeutic options. This is the reason and goal of founding SHIFTBIO. 

In-San Kim

MD. Ph.D.
Co-Founder 


- M.D. and Ph.D. from Kyungpook National University School of Medicine   

- Cancer research at M.D. Anderson Cancer Center 

- Principal research scientist at KIST 

- Professor of KU-KIST Graduate School of Converging Science and Technology 

- Expertise in cancer immunology and exosome therapy 

- Published over 300 papers (h-index: 79, as of 2022 July 12th) 


Confidence on exosome therapeutics will trigger a next-generation innovative paradigm shift. This is the driving force of foundation and growth of SHIFTBIO.

In-San Kim

MD. Ph.D.
Co-Founder 


- M.D. and Ph.D. from Kyungpook National University School of Medicine   

- Cancer research at M.D. Anderson Cancer Center 

- Principal research scientist at KIST 

- Professor of KU-KIST Graduate School of Converging Science and Technology 

- Expertise in cancer immunology and exosome therapy 

- Published over 300 papers (h-index: 79, as of 2022 July 12th) 


Confidence on exosome therapeutics will trigger a next-generation innovative paradigm shift. This is the driving force of foundation and growth of SHIFTBIO.

Gi-hoon Nam

MD. Ph.D.
Co-Founder 
Chief Scientific Officer


- MD. from Korea University School of Medicine 

- Ph.D. from KU-KIST Graduate School of Converging Science and Technology 

- Experience as a CEO in healthcare and platform businesses 

- Science advisor of Korea Medical Association 

- Research on cancer immunotherapy and exosome engineering at KIST, Dana-Faber Cancer Institute, and Harvard Medical School 


We aim to develop innovative holistic therapeutics to solve unmet medical needs. SHIFTBIO will keep our purpose and devote to fulfill the goal.

Gi-hoon Nam

MD. Ph.D.
Co-Founder
Chief Scientific Officer


- MD. from Korea University School of Medicine 

- Ph.D. from KU-KIST Graduate School of Converging Science and Technology 

- Experience as a CEO in healthcare and platform businesses 

- Science advisor of Korea Medical Association 

- Research on cancer immunotherapy and exosome engineering at KIST, Dana-Faber Cancer Institute, and Harvard Medical School 


We aim to develop innovative holistic therapeutics to solve unmet medical needs. SHIFTBIO will keep our purpose and devote to fulfill the goal.